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Summary
We present an overview of the research and achievements of applications of molecular
tools based on gene transfer and gene modulation (gene knock-down and knock-out),
aimed at enhancing food production, improving food properties and producing various
valuable compounds for human nutrition. Selected cases of genetically manipulated plants
(biofortification and allergene silencing) and animals (fish and livestock) are examined.
Promises and accomplishments are considered when giving topic examples of the poten-
tials offered by some applications of molecular biology for obtaining goods, among them
milk, with enhanced value, and of their impact on society at large.
Key words: biofortification, functional foods, gene silencing, gene suppression, health
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Introduction
This review focuses on the research, promises and
achievements of applications of molecular tools based
on gene transfer and modulation of genes (knock-down
and knock-out) carried out in plants and animals, aim-
ing at improving food properties and producing various
valuable compounds for human nutrition. The field is
huge since a great amount of research has already been
developed, and a number of promising results have been
achieved. Various documents concerning the state of the
art, in particular the regulatory aspects of experimental
and market releases of transgenic products, are available
on the websites of the institutional organizations involved
in agro-food policies, among them the International Ser-
vice for the Acquisition of Agri-Biotech Applications
(ISAAA) (1), the Food and Agriculture Organization of
the United Nations (FAO) (2), the International Centre
for Genetic Engineering and Biotechnology (ICGEB) (3),
the Joint Research Centre of the European Commission
(JRC) (4) and the European Food Safety Authority (EFSA)
(5).
This topic is a remarkable example of the controver-
sial interactions of science, society and politics which
characterize various innovations in biology research. Such
innovations, also known as 'bio-objects', leave the labo-
ratories and break into our every-day lives bearing their
load of promises and concerns. The products of gene
transfer and modulation, in fact, are constructed and
manipulated biologies potentially useful for enhancing
human life quality, balancing on the fine line between
the natural and the non-natural/artificial, and challeng-
ing conventional natural, cultural, scientific and institu-
tional orderings (6). Details of their impact on society
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can be found in specific literature (7–9) and in our previ-
ous works concerning the analysis of consumer accept-
ability and perceived risk related to genetically modified
organisms (GMOs) (10), and some bio-social implica-
tions of biology innovation and food (11,12). Moreover,
additional viewpoints can be found on the websites of
various associations and non-profit organizations involved
in bio-social issues and environmental protection.
Here we report a few selected cases of genetic mani-
pulation of plants and animals which we consider most
representative and relevant in scientific achievement for
their impact on society at large and from a historical
point of view. The aim is to build up a portrait of the
potentials offered by molecular biology for obtaining food
with enhanced value. This portrait is not meant to be a
complete magnum opus; conversely, it is intended to stim-
ulate readers' interest to further explore this fascinating
field. Besides the interest in the scientific aspects, in fact,
the production of fortified food, where the properties of
food and medicine are strictly linked, points our atten-
tion to the deep connection between food consumption,
culture and lifestyle, a relationship known since ancient
times.
Transgenic Crops for Improved Food Production
The first transgenic plant achievement dates back 30
years, when generations of antibiotic-resistant tobacco
(13–14) and petunia (15) were announced at the Miami
Winter Symposia of 1983 by three independent groups,
followed a few months later by a publication on trans-
genic sunflower expressing the bean phaseolin gene (16).
Since then, technical improvements and continuous suc-
cessful gene transfer have been reported in innumerable
plants and, according to the 2011 report of the ISAAA on
the Global Status of Commercialized Biotech/GM Crops
(1), nowadays 160 million hectares are cultivated with
biotech crops, with a globally upward trend. Soya bean,
maize, cotton and canola continued to be the principal
biotech crops in 2011, and herbicide tolerance has con-
sistently been the dominant trait.
Notwithstanding this commercial background, focus-
ing mainly on the industrial and feed crops which have
been genetically modified for traits useful to farmers as
well as biotech companies, there is a constant interest in
the scientific world in exploiting gene transfer techniques
for improving food properties and producing various
valuable compounds for human nutrition. This is reflect-
ed by the shift from the first generation of transgenic
plants to the second generation (plants with improved
quality and reduction of allergenic components) and fur-
ther (plant molecular farming, production of renewable
resources). Accordingly, many genetically modified plants
have been generated with the aim of producing pharma-
ceutical and nutraceutical compounds for use by humans,
a technology known as biopharming. Vaccine produc-
tion in transgenic plants is one of the best known exam-
ples of these new generation biotech crops. In particular
edible vaccines, produced in edible parts of the plants,
in their dual function of food and medicine, have been
designed to be easily delivered, and to overcome the
drawbacks of classical vaccine manufacturing based on
microorganisms and mammalian cells (17).
In some applications of gene transfer for relevant
compound production, both plants and animals have
been used to reach the same goal, and further experi-
mentation would help in identifying the best system,
considering efficiency, cost and acceptability of the prod-
ucts. This is the case of lactoferrin, a multifunctional
protein involved in several biological functions, such as
regulation of iron transport, antimicrobial defence and
antitumour mechanisms. Of the transgenic systems uti-
lized to produce human lactoferrin, besides yeast, trans-
genic cows and rice have also been successfully used.
The recombinant human lactoferrin (rhLF) is produced
on an industrial scale from Aspergillus awamori by Agen-
nix (Houston, TX, USA), from rice by Ventria Bioscience
(Sacramento, CA, USA) and from transgenic cows by
Pharming (Leiden, The Netherlands), and other compa-
nies in China and Argentina, as described below. In
plants, expression of rhLF has been also achieved in to-
bacco, potatoes, tomato, maize, barley and rice (18).
A number of reviews of the scientific literature pro-
duced over the years concerning genetically modified
plants, including the above-mentioned new generation
ones, have been produced; as the total amount of avail-
able papers and data have highly increased, they have
focused on various different aspects (among the latest
papers see 19–24).
In the present review, we concentrate on some se-
lected examples concerning gene transfer for improved
food production, and in particular for increasing nutri-
tional value, an approach also known as biofortification.
Biofortification of plant-derived foods appears to be a
promising strategy for the alleviation of nutritional defi-
ciencies. Various examples of genetically engineered crops
in order to increase their nutritional value through im-
provement of the level of vitamins/antioxidant com-
pounds are already available.
Modification of fatty acid content in food is a rele-
vant objective pursued both in animals (as described in
the section below) and plants, since scientific evidence
has implicated the quantity and/or quality of dietary
fats in the development of several illnesses, including
cardiovascular diseases, some cancers and arthritis. Ac-
cordingly, in canola (Brassica napus) seeds, high levels of
w-3 fatty acids have been accumulated by transferring
the genes of the enzymes involved in the fatty acid bio-
synthetic pathway (D6 and D12 fatty acid desaturases
from the commercially grown fungus Mortierella alpina
and the D15 fatty acid desaturase from canola) (25).
Several attempts have been made to engineer higher
lycopene levels in tomato fruits. With this aim, the bac-
terial crtI gene was introduced in tomato (26) resulting
in an unexpected threefold increase in b-carotene but not
in lycopene. Overexpression of lycopene b-cyclase (b-Lcy)
was obtained in tomato by introducing via Agrobacterium
a construct containing the Arabidopsis b-Lcy cDNA fused
with the tomato Pds promoter, which is up-regulated in
ripening fruits. Three transformants showed a signifi-
cant increase in fruit b-carotene content and an orange/
orange-red colour of fruits (27).
Diretto et al. (28) aimed at improving potato with a
mini-pathway of bacterial origin, driving the synthesis
of b-carotene (provitamin A) through three exogenous
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genes: phytoene synthase (CrtB), phytoene desaturase
(CrtI) and lycopene b-cyclase (CrtY). Expression of all
three genes under tuber-specific promoter control re-
sulted in tubers with a deep yellow phenotype. In these
tubers carotenoids increased approx. 20-fold, to 114 mg
per g of dry mass and b-carotene 3600-fold, to 47 mg per
g of dry mass, sufficient to provide 50 % of the
recommended daily allowance of vitamin A with 250 g
(fresh mass) of the transgenic potatoes.
A research project named BioCassava Plus (29) was
developed by a public network of researchers, aiming to
reduce micronutrient malnutrition by increasing the nu-
tritional value of cassava, a staple crop in Africa. The
objective of the project was to produce and field test a
transgenic variety of TME7 cassava enhanced with b-caro-
tene in Nigeria, such that it contains 40 mg of carotene
per g of dry mass and 40 mg of iron per g of dry mass.
Overcoming vitamin deficiency: the case of Golden
Rice
Among the crops already produced in the various
biofortification projects, Golden Rice has a ringside seat
since it is still the paradigmatic example of the potential-
ities that a transgenic crop can have, but also of the
problems it can cause. This project represents a scientific
breakthrough, being the first case of biochemical path-
way engineering. Moreover, Golden Rice was intended
as a product aiming at solving a major humanitarian
world problem rather than to benefit producers (30,31).
Nonetheless, it encountered fierce opposition, and there-
after few new transgenic Golden Rice lines have been
produced throughout the years.
The first paper concerning Golden Rice was pub-
lished in Science in 2000 (32). The authors stated that at
that moment as many as 124 million children worldwide
were deficient in vitamin A. This deficiency causes symp-
toms ranging from night blindness to xerophthalmia and
keratomalacia, leading to total blindness. Even subclin-
ical vitamin A deficiency can have broader consequences
in developing countries in terms of child morbidity and
mortality. Oral delivery of vitamin A was problematic be-
cause of the lack of infrastructure, therefore the supple-
mentation of a major staple food, rice, with provitamin
A seemed an effective strategy.
In an attempt to develop vitamin-A-producing rice,
a project started in 1992, led by Ingo Potrykus of the In-
stitute of Plant Sciences at the Swiss Federal Institute of
Technology (ETH, Zürich, Switzerland), together with
Peter Beyer of the University of Freiburg, Germany, with
the support of the Rockefeller Foundation (New York,
NY, USA) and others. Agrobacterium-mediated gene trans-
fer was used to introduce the entire b-carotene biosynth-
etic pathway into rice endosperm (the edible part of rice)
with different vectors. The vector pB19hpc combined the
sequences for a plant phytoene synthase (psy) originat-
ing from daffodil (Narcissus pseudonarcissus) with the se-
quence coding for a bacterial phytoene desaturase (crtI)
originating from Erwinia uredovora, placed under the con-
trol of the endosperm-specific glutelin (Gt1) and the con-
stitutive CaMV 35S promoter, respectively. The psy cDNA
contained a 59-bp sequence coding for a functional tran-
sit peptide, and the crtI gene contained the transit pep-
tide sequence of the pea Rubisco small subunit: this
plasmid directed the formation of lycopene in the endo-
sperm plastids. Provitamin A was produced in the ab-
sence of heterologous b-cyclase (which converts lyco-
pene to b-carotene): the absence of lycopene in Golden
Rice showed that the carotenoid pathway proceeded be-
yond the transgenic end point and thus that the endoge-
nous pathway must also be acting (33,34).
The scientists involved in the project intended to make
the technology freely available to developing countries
but had to face a number of legal constraints coming
from pending licences, since part of their financial sup-
port derived from the European Community Carotene
Plus project, whose industrial partners had rights to pro-
tect. An agreement was reached with Zeneca (Fernhurst,
UK), corporate sponsors of the Carotene Plus program,
and subsequently with most of the Intellectual and Tech-
nical Property Rights owners (some 32 companies and
institutions hold 70 patents for various technologies used
to create the enriched rice), so that it was possible to
grant freedom to operate to public research institutions
in developing countries to proceed in introducing the
trait into local varieties. The cut-off line between human-
itarian and commercial use, i.e. the maximum annual in-
come for a small-scale farmer to be exempted from roy-
alty payment, was set at US$ 10 000 (35).
A substantial improvement in the Golden Rice was
achieved by Paine et al. (36), from Syngenta biotechnol-
ogy company, who hypothesized that the daffodil psy
gene was the limiting step in b-carotene accumulation.
They identified a psy gene from maize and introduced it
in combination with the Erwinia uredovora crtI gene, used
to generate the original Golden Rice. This Golden Rice 2
(GR2) showed an increase in total carotenoids of up to
23-fold (maximum 37 mg/g) compared to the original
Golden Rice, now called GR1 (whose highest provitamin-
-A-producing line contained 1.6 mg per g of carotenoids
in the endosperm), and a preferential accumulation of
b-carotene. b-Carotene derived from GR2 was effectively
converted to vitamin A in humans (37).
An in-depth analysis of the potential economic ef-
fects of Golden Rice and the prospective impacts of
countries adopting this technology was given by Nielsen
and Anderson in 2003 (38). To have the greatest impact
at a low cost, Golden Rice varieties should be adapted
for widespread cultivation in Asia and should deliver as
much b-carotene as possible (39); the findings of Stein et
al. (40) suggested that related investments were worth-
while. The characteristics of Golden Rice may be trans-
ferred to locally adapted varieties and ecotypes in rice-
-growing countries to limit the reduction of biodiversity.
Both the original GR1 and GR2 originated from Japonica
rice cultivars; researchers were then backcrossing GR1
and GR2 lines with the Indica varieties popular among
Asian farmers. The initial perspective of making Golden
Rice cultivars available to farmers in a few years failed,
however, and the first field trial of Golden Rice in Asia
was only started in 2008 (41).
The most productive rice variety in Bangladesh,
BRRI Dhan-29, engineered at the International Rice Re-
search Institute (IRRI) in Los Baños, Philippines with the
b-carotene genes from corn, was successfully field-tested
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at the IRRI in February 2011. Besides BRRI Dhan-29, the
IRRI variety IR-64 and the Filipino variety RC-28 were
genetically engineered to have greater expressions of the
corn gene responsible for producing b-carotene. Accord-
ing to IRRI, if Golden Rice is shown to be safe and to
improve the vitamin A status, a delivery program will
be designed to ensure that Golden Rice is acceptable
and accessible in vitamin-A-deficient communities (42).
A considerable amount of literature and documents
concerning the opposition to the Golden Rice project has
been published, mostly signed by various institutions and
international non-governmental organizations (NGOs),
and can be found on the Internet. Besides risks related
to the environmental and biodiversity protections, bio-
-social concerns and disapproval of the policies adopted
for the empowerment of developing countries are the
most relevant issues pointed out against the adoption of
this crop. One of the most embraced criticisms of Gold-
en Rice is that the amount of transgenic rice to be con-
sumed during an everyday human diet to meet the daily
requirement of vitamin A would be largely unfeasible.
Figures reported by scientific papers, however, support
results quite divergent from this assumption (36,37),
proving the fact that the Golden Rice project has raised a
wealth of controversial opinions since its beginning and
the debate on the issue is far from being closed.
Still, several years after its first production, whilst
the scientific community values Golden Rice as a flag of
the humanitarian engagement of public research, oppo-
nents, on the contrary, present this bio-object as an ex-
ample of technology aimed at further enriching the mar-
kets of the already rich countries rather than elevating
the economies of the developing countries (43,44). This
assertion is well exemplified in the words of philoso-
pher Vandana Shiva, the environmental activist and eco-
feminist, one of the leaders and board members of the
International Forum on Globalization and a figure of the
global solidarity movement known as the alter-globali-
zation movement: 'While the complicated technology
transfer package of Golden Rice will not solve vitamin
A problems in India, it is a very effective strategy for
corporate take-over of rice production, using the public
sector as a Trojan horse' (45).
The promise of resveratrol for healthier transgenic
food production
Stilbenes are natural, biologically active phenolic com-
pounds occurring in a number of plant families, includ-
ing Vitaceae and (within this family) Vitis vinifera L., which
is one of the most economically important horticultural
crops. In particular, resveratrol (3,5,4'-trihydroxy-trans-
-stilbene) and viniferins are present in grapevine as con-
stitutive compounds of the woody organs (roots, canes,
stems) and as induced substances (in leaves and fruit)
acting as phytoalexins in the mechanisms of grape re-
sponse to pathogens and abiotic stresses (46,47). Several
other fruits and vegetables naturally produce stilbenes,
as resveratrol has been found in cranberries, blueberries,
mulberries, peanuts and jackfruit (48).
Stilbenes also exhibit a broad spectrum of antibiotic
and pharmacological activities, and have generated con-
siderable interest as nutraceuticals, owing to their di-
verse health-promoting properties and their supposed
role against cardiac ailments and cancer. The first evi-
dence of stilbene synthesis in Vitaceae species was re-
ported by Langcake and Pryce in 1976 (49). Since then,
intense research aimed at elucidating the role of stilbenes
has been carried out, although the topic still needs fur-
ther studies. Resveratrol, one of the best known plant
secondary metabolites, has also been detected in red
wine (it is synthesized in the berry skin and the macera-
tion period during winemaking allows for its extraction
into the resulting wine) (46).
At the beginning of this millennium, much empha-
sis was given to the so-called French paradox by the me-
dia, i.e. the fact that French people suffer a relatively low
incidence of coronary heart disease, despite having a
diet relatively rich in saturated fats: this conflicting data
was hypothetically explained by the consumption of red
wine, which should decrease the incidence of cardiac
diseases (50,51). Thereafter, a great number of studies in
model animals and epidemiological observations in hu-
mans concentrated on proving the effects of polyphenols
and resveratrol in wine, as well as in determining the
most suitable dose assumed to produce these beneficial
attributes.
Accordingly, moderate wine consumption has been
proposed in the prevention of various chronic patholo-
gies, in particular those related to cellular oxidative stress,
including diabetes, high blood pressure, atherosclerosis,
cholesterol reduction and certain cancers (52–55). Other
studies (56,57), however, raised doubts about the healthy
effects of dietary resveratrol consumption. Recently, works
conducted on the beneficial effects of resveratrol at the
University of Connecticut Health Center (UCHC, Farm-
ington, CT, USA) have been subjected to an extensive re-
search misconduct investigation by UCHC itself and the
US Office of Research Integrity (ORI, Rockville, MD,
USA) (58,59). The significance of this case of fabrication
and/or falsification of data, however, seems to be an ex-
ample of scientific research fraud rather than an invali-
dation of the many studies on the health benefits of re-
sveratrol. Possibly, the potentialities of this compound
have been overestimated and at the present time, the
long-term effects of supplementation of resveratrol and
other stilbenes in human diet still need to be ascertained.
Nonetheless, the interesting biological properties and
the potential positive effects of these compounds have
driven many scientists to study them and to attempt the
production of functional food with an enhanced content
of resveratrol and related compounds via gene transfer.
The role of resveratrol as a phytoalexin has been widely
studied, in particular in the defense against fungal patho-
gens (60).
Transfer of stilbene-encoding genes to plants unable
to produce (or having a limited production of) phyto-
alexins has been attempted, starting from the early 1990s.
The first gene transfer experiment was performed by trans-
ferring a stilbene synthase gene from peanut (Arachis
hypogea) to tobacco cells, resulting in de novo resveratrol
synthesis after induction with UV-light and an elicitor
(61). Genes involved in the biochemical pathway of stil-
benes in grapevine were also used in gene transfer expe-
riments, such as two grapevine genes coding for stilbene
synthase to tobacco. The obtained transgenic tobacco
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plants were more resistant to Botrytis cinerea infection than
the control (62). Since those pioneering works, stilbene
synthase genes from grapevine or peanut have been trans-
ferred to a number of plants to increase their tolerance/
resistance to plant pathogens or to exploit their positive
effects on human health; in some cases both aims were
pursued.
Among the gene transfer experiments with the final
goal of improving the health protection properties of dif-
ferent plant species, genetically modified alfalfa (Medi-
cago sativa) was used as a model in applying biotechno-
logical approaches to cancer prevention. This transgenic
alfalfa was generated with a peanut cDNA encoding re-
sveratrol synthase, which produced trans-resveratrol-3-O-
-b-D-glucopyranoside (RG), whose constitutive accumula-
tion increased resistance to Phoma medicaginis (63). Trans-
genic alfalfa or synthetic RG included in mice diets were
unable to inhibit the formation of preneoplastic lesions
(that directly correlate with the risk of colon cancer and
tumour size in humans) in the colon of mice, probably
due to the metabolism and biological uptake of the com-
pound in the upper gastrointestinal tract, but when these
diets were supplemented with the exogenous enzymes
b-glucosidase (64) or a-galactosidase (65), the develop-
ment of the preneoplastic lesions was significantly reduced.
Resveratrol was extracted and purified from trans-
genic tobacco plants. Having observed an increased ac-
cumulation of human breast adenocarcinoma cells in G0
and G1 phases of cell cycle in the cells treated with this
resveratrol as compared to the untreated cells, it has been
concluded that resveratrol from transgenic plants merits
further investigation as a potential cancer chemopreven-
tive agent in humans (66).
Stilbene synthase genes from Vitis vinifera were trans-
ferred to Lactuca sativa, resulting in a transgenic red let-
tuce capable of producing resveratrol in amounts higher
than red wine (67). Fruit tree species were also geneti-
cally modified with genes coding for resveratrol synthe-
sis. cDNA encoding stilbene synthase from V. vinifera,
transcriptionally regulated by an enhanced cauliflower
mosaic virus (CaMV) 35S promoter, was transferred to
Spadona pear (Pyrus communis) resulting in piceid and
resveratroloside accumulation in transgenic plants (68).
A similar approach was adopted in Elstar and Holstein-
er Cox apples (Malus domestica), where stilbene synthase
gene (Vst1) transfer caused the accumulation of a resve-
ratrol derivative, trans-resveratrol-3-O-b-D-glycopyrano-
side (piceid), in fruit tissues (69). The possible influence
of the novel biosynthetic pathway on the accumulation
of other phenolic compounds naturally present in apple
fruit was investigated, and in none of the transgenic apple
lines that accumulated piceid was a negative correlation
between levels of piceid and the amounts of flavanols,
flavonols, phloretin derivatives and hydroxycinnamic acids
observed, except for the flavonol content, which slightly
decreased (70).
Stilbene synthase production induced by transferred
exogenous genes has been obtained in a wide range of
plant species, including tomato (71), barley and wheat
(72–74), rice (75), poplar (76), pea (77), hop (78), and purple
sweet potato (79). These experiments were usually aimed
at the production of transgenic plants with increased re-
sistance to fungal pathogens, but the positive effects of
resveratrol on human health were also considered. How-
ever, not all the resulting transgenic lines showed an in-
creased tolerance to pathogens when specific bioassays
were performed.
While stilbenes can be recovered as an extract from
a selected number of plants, these products are not suit-
able for many applications in the food/pharmaceutical
sectors due to high levels of impurities as well as the
overall low concentration of resveratrol and its deriva-
tives in the extract (80). Therefore, it is important to de-
velop an effective method of producing this compound
commercially. To deliver a highly defined and enriched
resveratrol product, hairy root cultures of peanut were
studied as a bioproduction system for resveratrol and
associated derivatives. In this system, 99 % of the total
resveratrol produced was secreted into the culture me-
dium at levels of 98 mg per mg of the medium dried
extract (80).
Given the increased interest in these compounds and
the increasing number of experiments aimed at the gen-
eration of transgenic plants overexpressing them, some
comprehensive reviews have recently been published,
focusing on the role and activity of resveratrol (47), its
molecular engineering in plants (81,82), and methods for
obtaining it, from plant extraction to chemical synthesis
and biotechnological production (83,84). In these papers
gene and promoter options are discussed, as well as fac-
tors modifying transgene expression and epigenetic modi-
fications, the incidence of these compounds in plant me-
tabolism and development, and the use of biotechnology
through recombinant microorganisms and plant cell sus-
pensions.
Transgenic Animals for Improved Food
Production
Gene transfer in animals was pioneered at the end
of the 1970s, starting with a mouse expressing foreign
DNA sequences of tumour virus SV40 (85), and nowa-
days this technique has been successfully applied in a
considerable number of farm animals such as rabbit, pig,
sheep (86), cattle (87) and goat (88).
Direct microinjection of genetic material into the pro-
nuclei of fertilized one-cell eggs to be implanted into the
oviducts of pseudopregnant surrogate female mice has
been the first effective strategy developed (89) and, even
though laborious, costly and hampered by relatively low
efficiency and species-dependent embryo survival, is still
reported as the most accepted method of production of
transgenic animals (90). Alternatively, starting from the
pioneering studies developed in the 1970s based on retro-
virus vectors (91), lentiviral vectors have been efficiently
used for microinjecting fertilized eggs, unfertilized oocytes
and zygotes, and nowadays lentivirus-mediated trans-
genesis is the most strongly emergent technology for de-
livering genes as well as for transfecting synthetic small
interfering RNA (siRNA) molecules aimed at targeting
gene knockdown (90,92). The combination of somatic cell
nuclear transfer, an established tool to yield copies of se-
lected individuals in different animal species, with ge-
netic engineering is currently reported as the most suit-
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able method for generating transgenic large animals for
both agricultural and biomedical applications (93).
It is worth remembering that male germinal cells
(spermatozoa and spermatogonial stem cells) have been
used to direct the transfer of exogenous DNA into fe-
male cells for generating transgenic animals (94). Embry-
onic stem cell-mediated gene transfer has also been de-
veloped (95) by inserting a desired DNA sequence via
homologous recombination into an in vitro culture of these
totipotent cells, which are then incorporated into an em-
bryo at the blastocyst stage of development. DNA con-
structs can also be transfected by electroporation into fe-
tal cells, such as fibroblasts, which can thereafter be used
to clone transgenic animals by nuclear transfer (96). Com-
bination of classical breeding with gene transfer may also
be used, as in transgenic cows which, besides insertion
of a desired gene into embryos, can be produced by mat-
ing wild type cows with genetically modified bulls for
the generation of transgenic progeny (97).
To date, according to the results obtained in animals
relevant to food production, gene transfer seems to be a
costly strategy, and not as efficient as initially promised,
compared with conventional selection. Moreover, trans-
genic farm animal production for biomedical applications
encountered more acceptability and provoked less pub-
lic concern, thus influencing the industrial application of
GM animals. Consequently, gene transfer has primarily
been used for biomedical rather than agricultural appli-
cations. In medicine, genetically modified pigs have been
adopted as organ sources for xenotransplantation (98).
The generation of transgenic mice capable of mimicking
human genetic diseases provides a suitable whole ani-
mal model for studying human genetic diseases in order
to develop pathological and pharmacological studies (99).
The production of drugs for pharmaceutical use is an-
other relevant application of transgenic animals, in par-
ticular to overcome the limitation of recombinant bacte-
rial systems, which are less suitable for producing complex
proteins such as monoclonal antibodies or coagulation
blood factors. Moreover, compared to plants, the high
yield and low-cost production as well as the high qual-
ity of the proteins obtained are the features which make
animal systems appealing tools (100). The most common
system is milk from transgenic farm mammals; never-
theless, chicken egg white and blood, seminal plasma,
urine, silk glands and insect larval haemolymph have
also been exploited (100).
As for food improvement, animals have been genet-
ically modified to obtain improved livestock and quali-
-quantitatively enhanced food sources. Productivity traits,
such as feed conversion, rate of gain, reduction of fat,
and improved quality of meat are the most pursued ob-
jectives (101). The productivity traits are however quan-
titative, thus controlled by numerous genes, of which only
a few are presently known. For this reason, besides the
current low level of public acceptance, the progress of
agricultural applications of livestock transgenic technol-
ogy is less developed compared to biomedical applica-
tions. Among the hundreds of quantitative trait loci (QTL)
already mapped in livestock, two mutations underpin-
ning the QTL have been identified in dairy cattle: the
first concerns the 1DGAT1 (acyl-CoA:diacylglycerol acyl-
transferase) locus on chromosome 14 as a gene contrib-
uting to fat composition in milk (102) and the second
concerns the ABCG2 (ATP-binding cassette, subfamily G
(WHITE), member 2) locus on chromosome 6 as a gene
contributing to fat and protein concentration in milk (103).
More advanced is the knowledge of monogenic traits
of economic and biological interest, and a number of caus-
ative mutations have already been identified, as reported
in the valuable database Online Mendelian Inheritance
in Animals (OMIA) (104), where numerous single-locus
traits are described in 192 animal species other than hu-
man and mouse, including food sources as interesting as
cattle, pig, sheep, goat, chicken and horse, according to
the different food ethics of various countries, which ei-
ther assign the status of food source to animals or desig-
nate their consumption as a taboo (105).
In the near future, the achievements of genome proj-
ects will offer useful information for better understand-
ing of the most economically important genes in live-
stock species in order to accomplish the selection for
desirable traits, or conversely, against undesirable traits
(106), and in the main species, like bovine ones, genome
sequencing has already been accomplished (107).
Growth enhancement in transgenic animals
Growth enhancement is one of the most pursued
applications of transgenic techniques. Pigs, fish and cat-
tle have been engineered in an attempt to provide more
food per animal, generally by transferring growth hor-
mone genes (108). Growth hormone (GH) is a peptide
hormone naturally synthesized, stored, and secreted by
the pituitary gland, which stimulates growth, cell multi-
plication and regeneration (known as anabolic effects) in
humans and other animals. Over- and under-production
of GH are related to relevant pathologies.
Production of superfish has received the most atten-
tion because of its success in generating marketable prod-
ucts in shorter periods of time and with lower produc-
tion costs, and has been applied to a wide range of fish
species including the coho (Oncorhynchus kisutch), Atlan-
tic (Salmo salar) and Japanese (Oncorhynchus masou) sal-
mons. As detailed in Maclean and Laight's review (109),
the growth enhancement of fish species can be dramati-
cally improved by transgenesis based on the GH gene:
in the Atlantic salmon and coho salmon, more than ten-
fold larger G0 fish than control counterparts were ob-
tained, and in Tilapia sp. up to more than threefold mass
increase was recorded. Results in carp, northern pike
and channel catfish were not so dramatic, but still rele-
vant, possibly because of the considerable strain selec-
tion over many hundreds of years of human exploitation
rather than because of the failure of transgenesis.
Some North American multinational companies have
already developed transgenic salmon, trout, and tilapia
designed to grow faster than their conventional siblings.
This is the case of the AquAdvantage® Salmon produced
by AquaBounty Technologies (Waltham, MA, USA), which
presents the product with the following words: 'AquAd-
vantage® Salmon (AAS) includes a gene from the Chi-
nook salmon, which provides the fish with the potential
to grow to market size in half the time of conventional
salmon and, in all other respects, AAS is identical to
other Atlantic salmon' (110). This salmon, which repre-
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sents a profitable solution to increasing fish demand in
the coming years, will be recorded as the first transgenic
animal for human consumption approved by Food and
Drug Administration (FDA) (111). A lengthy authoriza-
tion process started in 1995, when AquaBounty Technol-
ogies applied for official US Government approval to
develop this salmon commercially. In 2010, the FDA an-
nounced that there was enough information available to
review the GM salmon, and in May 2012 it completed its
environmental assessment. In December 2012, a draft was
published declaring that the production of the GM fish
is unlikely to have any detrimental impact on the wider
environment, opening the doors for commercialization
and yet again raising a strong anti-GMO reaction (112).
Initially, GH genes from mammals, principally hu-
man, bovine and rat, were the first exogenes used for
developing the superfish under the control of the metal-
lothionein B promoter. Recently, sequences derived from
fish itself ('all fish' genetic material) carrying both pro-
moters and genes from fish origin have been employed
on the basis of a presumed higher likelihood of accept-
ability by consumers, as in the case of cisgenic plants
(113). Oppositions to genetic manipulation of animals, as
for plants, however, seem to ignore this assumption. In
2001, the European Patent Office (EPO) granted its first
patent (Patent No. 0578653) on genetically engineered
fish concerning a gene construct for production of trans-
genic fish produced by Canadian Seabright Corporation
Ltd., Toronto, Canada (114). The construct carried a pro-
moter sequence of the antifreeze protein derived from
ocean pout. This promoter proved to provide better gene
expression and regulation in the fish (115). For instance,
transgenic Atlantic salmon, generated with all fish GH
chimeric gene constructs carrying this promoter linked
to a chinook salmon GH, presented an amazing growth
rate since, when one year old, the average increase was
2- to 6-fold and the largest transgenic fish was 13 times
bigger than the non-transgenic controls (116).
Transgenic superfish have been studied in depth and
specific tests have been used to measure their perfor-
mance, including manoeuvrability, speed of escape re-
sponse, sprint speed and propulsive efficiency. Some evi-
dence to support the view that growth-enhanced trans-
genic fish may be inferior to their wild-type counterparts
has been published, since in transgenic rainbow trout a
behaviour related to an increased predation mortality
has been seen, and in transgenic coho salmon a lowered
swimming performance (117,118) has been observed. Ap-
plication of gene transfer to fish is relatively simple, but
the 'mobility' of transgenic fish and the consequent need
for containment are related problems and, besides strict
containment measures, sterilization has been proposed
to overcome this disadvantage (109,119).
GH gene transfer has also been exploited in pigs and
resulted in transgenic animals having faster mass gain,
higher (17 %) efficiency in converting feed into meat and
reduced (down to one-fifth) fat in the carcass compared
to the wild-type counterparts. However, various delete-
rious effects have also been observed (120). This is the
case of a pig named Beltsville pig after the Agricultural
Research Station in Beltsville, MD, USA, where it was
generated, and nicknamed super-pig for its large size.
This animal was produced by zygote microinjection with
a construct carrying an ovine metallothionein 1a-ovine
growth hormone fusion gene. High-level expression of
the transgene resulted in a dramatic reduction in carcass
fat with a concomitant increase in carcass protein and
moisture content as compared to the control littermates.
However, the high expression of this transgene due to
its ineffective regulation hindered these results, and vari-
ous health problems (lethargy, lameness, uncoordination,
exopthalmus, gastric ulcers, severe synovitis, degenera-
tive joint disease, pericarditis and endocarditis, cardiomeg-
aly, paraketosis, nephritis, and pneumonia) related to its
enormous size were the side effects in this experimental
pig, which at the end could not support its own mass
(120, 121). Such severe problems were thought to be the
result of the constant high level of circulating GH, but at-
tempts to control expression by the use of inducible pro-
moters have not yet been successful. Consequently, the
super-pig could never be used for ethical reasons, was
therefore put down to end its suffering and served as an
example for critics of transgenic animal research (122).
In sheep, transgenic GH lambs did not present fast-
er growth nor more efficient feed conversion compared
to controls; however, they were much leaner and pre-
sented a lack of body fat, this latter trait being attributed
to the result of hyperglycemia and glycosuria (123,124).
Transgenic lambs with elevated GH also had a number
of other pathologies, including joint problems and de-
generative kidney disease (120).
Overexpression of GH genes in transgenic mice has
been applied in order to understand the effects of long-
-term GH excess. In these models, bovine, ovine or rat
GHs (i.e. hormones with actions closely resembling, if
not identical to, those of endogenous mouse GH) exhib-
ited growth enhancement, increased adult body size, re-
duced lifespan and various endocrine and reproductive
abnormalities, i.e. a variety of direct and indirect actions
at the hypothalamic, pituitary, gonadal, and reproduc-
tive tract levels (125).
Quality improvement of food
Production of food with improved quality, as a re-
sult of enhanced/enriched/reduced contents of specific
components, is another main goal of livestock genetic
improvement. Modification of polyunsaturated fatty ac-
ids (PUFAs) is one of the most relevant goals, as clinical
studies have shown that long-chain w-3 PUFAs have a
beneficial effect on human health, whilst high levels of
n-6 PUFAs in human bodies are closely related to cancer,
cardiovascular diseases and mental disorders (126). Since
mammals lack n-3 desaturases, the n-3 and n-6 PUFAs
are not interconvertible. Accordingly, products from sea
fish are the main dietary source of n-3 fatty acids for hu-
mans. For this reason farmers and the livestock produc-
tion industry feed animals with flaxseed, fish meal or
other marine products for enriching foods, contributing
on the other hand to the depletion of marine fish stock
as well as running the risk of potential contamination of
fish products with mercury and other chemicals (96).
Following a promising experiment where exogenous
expression of a humanized fat-1 gene (hfat-1) encoding
an n-3 fatty acid desaturase from Caenorhabditis elegans
in mice resulted in a significant increase of n-3 fatty ac-
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ids in various tissues and in milk, as well as in a sharply
decreased ratio of n-6/n-3 fatty acids (127), this exogene
was transferred in pig and cow to produce healthier live-
stock. In both experiments, fetal fibroblast cells were used
for gene transfer and transgenic animals were cloned from
these cells. In piglets, in the major tissues (muscle, liver,
kidney, heart, spleen, tongue, brain and skin) of the vari-
ous founder animals recovered, and in their offspring,
n-3 PUFAs were significantly increased, while n-6 PUFAs
were decreased, resulting in a greatly reduced n-6/n-3
ratio (96).
In cows, only a transgenic calf was generated; how-
ever, this animal exhibited promising features. Analyses
of fatty acids from ear tissues, in fact, showed that all
major n-3 fatty acid peaks were elevated, whilst all ma-
jor n-6 peaks were at a lower level, thus proving suitable
expression of n-3 desaturases (128). Moreover, this ani-
mal grew healthy and, after artificial insemination, natu-
rally delivered a healthy calf. The content of n-3 PUFAs
in milk was significantly increased and the ratio between
n-6 and n-3 was reduced fourfold compared to the non-
-transgenic counterparts. These results showed that the
transgenic cow was capable of normal reproduction, the
transgene was properly expressed in the mammary gland
and the n-3 fatty acids were enriched in the milk (128).
Milk production by transgenic animals
Milk-producing transgenic animals are the objects of
extensive research aimed at manufacturing compounds
to be available in, or extracted at low cost from, their
milk. Transgenic animals containing human proteins in
their milk are also known as transpharmers and various
animal species have already been adopted as transpharm-
ers (129).
The expression vector carrying the gene encoding for
the protein of interest fused to milk-specific regulatory
elements is generally introduced into the germline of the
chosen species via pronuclear microinjection of one-cell
embryos or transfection into a primary cell population
suitable for somatic cell nuclear transfer. Mice are main-
ly used for experimental assays and for testing the con-
structs prior to generating larger transgenic founder ani-
mals. Transgenic rabbits are not suitable for large-scale
production because of their small lactation yield and la-
bour-intensive milking, whilst sows have been success-
fully used for the considerable amount of milk (100–200
L) they can produce. Transgenic ruminants are obvious
candidates since thousands of years of genetic selection
have yielded breeds of sheep, goats, and cattle that can
produce prodigious quantities of milk (129).
More than 60 therapeutic proteins, including plasma
proteins, hormones, monoclonal antibodies, vaccines, cyto-
kines, enzymes, fibrinogen and insulin have already been
produced experimentally from the milk of transgenic cows,
sheep and goats (97). Amongst them is the anticoagulant
antithrombin (ATryn), the first biological drug from ge-
netically engineered animals which was manufactured
by the US company GTC Biotherapeutics (Framingham,
MA, USA) from the milk of a transgenic goat and ap-
proved in February 2009 by the US Food and Drug Ad-
ministration (see the FDA archive, 130). Transgenic milk
has also been exploited for industrial applications, like
the high-value polymers produced in goat milk as a re-
sult of exogenous expression of the silk gene from spider
(131).
Gene transfer has been used for improving livestock
growth, and for health and survivability of milk-fed new-
borns. In pigs, for instance, where milk production is a
limiting factor for piglet growth, overexpression of bo-
vine a-lactalbumin, which plays a key role in the lactose
synthesis and regulation of milk volume, resulted in in-
creased milk lactose (thus an enhanced carbohydrate
source) associated with a 20–50 % increase in milk yield.
As a result, the growth and survival of suckling piglets
improved significantly (132).
The introduction of new antimicrobial properties into
milk is a desirable aim to provide passive immunity for
the suckling young, but also for humans consuming the
milk. This was the goal of a work aimed at overexpress-
ing the human form of the antimicrobial protein lyso-
zyme in the goat's milk, which was used for feeding pig-
lets as human models and resulted in a beneficial effect
on their intestinal microflora (133).
The mammary gland of dairy cattle is considered ideal
for large-scale production of heterologous proteins due
to its large capacity for protein synthesis, efficient secre-
tion, and low feed and housing costs of dairy animals
compared to in vitro fermentation or tissue culture sys-
tems (18). Accordingly, a number of research projects have
concentrated on transgenic milk production both for
medical and nutritional properties. As functional food,
engineered milk links together the attributes of medici-
nal and nutritional, becoming a medicinal food. Bovine
milk, in fact, is an important food for humans, with a
consumption of milk and milk products per capita vari-
able among world regions.
Cow's milk is a source of lipids, proteins, amino ac-
ids, vitamins and minerals and contains immunoglobu-
lins, hormones, growth factors, cytokines, nucleotides,
peptides, polyamines, enzymes and other bioactive pep-
tides (134). In western societies, however, a decreasing
trend in milk consumption has been noted during the
last decades, probably due to claimed negative health ef-
fects that have been attributed to milk and milk prod-
ucts because of its high saturated fatty acid content (134).
Thus improved milk, particularly as far as qualitative at-
tributes are concerned, is an attractive goal. Here we con-
sider an improvement based on additional gene transfer,
whilst some interesting perspectives of gene modulation
and silencing are reported in the next section.
Reducing the susceptibility of livestock to pests and
diseases via genetic engineering has long been an ambi-
tious goal, which would also result in improved produc-
tion and reproductive performance and could ultimately
provide safer food products of superior quality (135).
This concerns, for example, mastitis, a bacterial infection
of the mammary gland, which is one of the most costly
diseases in cattle breeding, and can also result in death.
In dairy cattle, mastitis is mostly caused by Staphylococ-
cus aureus infection, a pathogen particularly hard to con-
trol with antibiotic treatments. A transgenic strategy has
proved to be promising for the prevention of mastitis in
cattle by expressing exogenous lysostaphin, an endopep-
tidase with lytic properties on a Staphylococcus cell wall.
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In fact, transgenic cows producing lysostaphin in their
milk showed a high degree of protection when challenged
with S. aureus. Moreover, increased antimicrobial proper-
ties in the milk of mice associated with the overexpres-
sion of the endopeptidase lysozyme or lactoferrin pro-
vided evidence for the potentials offered by this approach
to prevention of mastitis in dairy cattle (135).
As for the enhancement of the functional properties
of dairy milk via a transgenic approach, some promising
results regard the production of milk with less lactose or
cholesterol (136). New Zealand has been a leader in re-
search concerning transgenic milk production and, since
2000, scientists at AgResearch (137) have been success-
fully producing transgenic cows that yield modified milk
containing therapeutic proteins to treat human diseases.
Various experimental field trials, in proper containments,
have been approved by the Environmental Risk Manage-
ment Authority of New Zealand (ERMA). Among the
various results, qualitatively improved dairy milk com-
position with higher casein content (up to 20 % more)
was achieved by transferring additional copies of the
genes encoding bovine b- and k-casein (138). This result
was quite interesting, considering the relevance of casein
in milk composition, representing 80 % of the overall
proteins, having important nutritional and processing
properties and therefore being one of the prime targets
for milk composition improvement. Moreover, this was
the first proof that transgenic technology could be used
to modify milk composition in cows following previous
research focused on transgenic cows to produce thera-
peutic recombinant proteins.
The production of cheap surrogates for human breast
milk for the newborn has been a relevant goal in the
food industry and as an alternative to infant formula,
transgenic technology for producing cow's milk with in-
creased similarity to the properties of human milk has
been pursued by a few companies in different parts of
the world. Besides the absence of the species-specific
quali-quantitative composition of minerals, carbohydrates,
proteins, fat, prebiotics and antibodies which make hu-
man milk unique to a baby's nutrition, hard digestibility
and allergenicity are the most relevant drawbacks of
cow's milk (139).
Human lactoferrin, the iron-binding protein also pre-
sent in human breast milk and in particular in colostrum,
has been regarded as a suitable candidate to enrich cow's
milk on the basis of its recognized physiological proper-
ties, which are anti-inflammatory and have antipatho-
genic functions and roles in iron absorption and/or ex-
cretion in newborns as well as in the promotion of intestinal
cell growth (18,135,140). In milk, recombinant human lac-
toferrin (rhLF) has been overexpressed in concentrations
high enough to meet the needs of human children, with
the goal of obtaining functional dairy milk with increased
protection against infections and improved gastrointes-
tinal health properties. The obtained recombinant protein
was highly similar to the human natural counterpart for
its most prominent biological activities, i.e. iron binding
and release and antibacterial activity, thus paving the way
for safe usage of rhLF in humans (141). Moreover, that
work proved the potential of transgenic cattle as biore-
actors in terms of capacity (140). The milk was obtained
from the female offspring of one of the first notable trans-
pharmer animals, Herman the Bull, which was engineer-
ed to carry a gene for lactoferrin by Gen Pharm Inter-
national (Mountain View, CA, USA) (142). Herman fathered
eight calves in 1994, following a breeding program es-
tablished at Gen Pharm's European laboratory (Leiden,
The Netherlands); in 2004 was euthanized for stopping
osteoarthritis sufferance and, after taxidermy mounting,
exposed as bio-object icon in the Naturalis Biodiversity
Center, Leiden, the Netherlands (143).
In 2011, the media gave resonance to two experiments
occurring in laboratories in different parts of the world
(Argentina and China), both claiming the first achieve-
ment, aiming at producing transgenic cow's milk using
human genes that allow the animal to produce the equi-
valent of a (human) mother's milk. On April 2, 2011, The
Telegraph announced that the Chinese Academy of En-
gineering had led a research which generated cows pro-
ducing human lactoferrin (144). What was new in this
research, according to official statements, was that, after
seven years of research, by using a property technology,
the produced milk contained the highest level of lacto-
ferrin in the world. The Chinese Ministry of Agriculture
approved the testing on genetically modified dairy cows
for human breast milk, and official media reported that
this milk would become the first transgenic animal prod-
uct in commercial use with prospects for use in infant
formula milk powder, health foods and medicines.
A few days later, the Argentinean National Institute
of Agricultural Technology (INTA; Buenos Aires, Argen-
tina) announced that a cloned cow, named Rosita ISA
was the first cattle born in the world with two human
genes coding for proteins (lysozyme and lactoferrin)
present in breast milk (145). The lysozyme is an enzyme
present in (human) breast milk at high concentrations
during the first week of lactation. Lactoferrin exists in all
mammals but is specific to each species, and therefore
bovine lactoferrin does not affect humans. 'As an adult,
the cow will produce milk that is similar to humans',
INTA's statement said. The goal was to increase the nu-
tritional value of cow's milk with lactoferrin, which pro-
vides infants with antibacterial and antiviral protection
and improves iron absorption, and lysozyme, which is
also an antibacterial agent.
Transgenic milk production, and in particular the
above-reported case of AgResearch in New Zealand, has
been rightly considered a remarkable case of the impact
of scientific innovation on society, and has been a case
study in analyzing the contested representation of the re-
search in its promotion, its governance, and the opposi-
tion sparked amongst environmental/antigenetic modifi-
cation groups, including the Maori community (146). Quite
interesting, and worth devoting significance to, was the
opposition against this research, and the government en-
vironmental risk management authority (ERMA) ap-
proval of the experimental field trials, conducted by the
New Zealand women's organization Mothers Against Ge-
netic Engineering in Food and the Environment (MADGE),
a 'network of politically non-aligned women who are ac-
tively resisting the use of genetically engineered mater-
ial in our food and on our land', led by artist Alannah
Currie (147). In particular, two campaigns, a masquerade
in the parliament building and billboards displayed in
Wellington and Auckland, New Zealand, based on a
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strong, creative and provocative symbolic communica-
tion, were renowned for their astonishing approach and
related media reactions. They were meant, really, to con-
dense metaphors and visual and emotional excesses in
order to provoke a public debate about the social and
cultural ethics of genetic engineering in New Zealand.
The topic, on the other hand, was quite inspiring, consi-
dering emotional and cultural implications concerning ani-
mal milk and mother's breast milk.
Gene Modulation and Silencing for Improved
Food
Molecular techniques for food improvement have
mostly been based on gene transfer into target genomes.
Nonetheless, gene silencing of undesired traits would be
a promising tool, and it is expected that besides (or maybe
instead of) improvement based on traditional gene trans-
fer, further research will be focused on adopting this stra-
tegy in plants and livestock.
Exogenous RNA-based gene regulation
Besides the various kinds of ribonucleic acids (RNA)
present in organisms, such as messenger (mRNA), ribo-
somal (rRNA) and transfer (tRNA), many eukaryotes have
an additional, highly abundant class of non-coding RNAs
(20 to 30 nucleotides) generally referred to as small RNAs
(sRNAs) (148). In the cell, sRNAs have various functions,
such as regulation of gene expression, development and
chromatin structure, and represent an important plant de-
fense mechanism against viral infections and transpo-
sons. sRNAs are distinguished in two main classes: micro
RNAs (miRNAs) and small interfering RNAs (siRNAs).
The first derive from single-stranded endogenous RNA
transcripts folding themselves up to produce imperfect
double-stranded stem loop precursors, whilst siRNAs
are processed from long, perfectly double-stranded RNA
(dsRNA) precursors from endogenous (trans-acting siRNAs,
natural antisense transcript-derived siRNAs, heterochro-
matic siRNAs) or exogenous sequences, for example from
viruses, which are cleaved in the cell to short RNA frag-
ments (149).
Numerous studies have demonstrated that siRNAs
in cultured cells of plants and animals can trigger highly
efficient gene silencing through degradation of the en-
dogenous mRNA, whose sequence is complementary to
the siRNAs. The most commonly applied methods for
gene silencing based on siRNAs are virus-induced gene
silencing (VIGS), RNA interference (RNAi), miRNA as in
the case of artificial miRNA (amiRNA) and miRNA-in-
duced gene silencing (MIGS) (150).
The process of introducing RNA molecules into cells
to suppress the expression of a gene of interest, for ob-
taining RNA interference (RNAi), is nowadays a crucial
tool in functional genomic studies, and various technol-
ogies have been developed. In plants, several constructs
adapted to Agrobacterium-mediated gene transfer or vi-
rus vectors are available (151), whilst in animals trans-
fection via liposomes, electroporation and viral gene
transfer via recombinant viral vectors based on retro-
virus, adeno-associated virus, adenovirus, and lentivirus
are the most applied strategies (152). Further develop-
ment in the knowledge of plant and livestock genomes
is expected to enlarge the list of candidate genes to be
modulated for useful application in enhanced food pro-
duction.
RNAi in plant-derived food
In plants, RNAi can be used to improve plant nutri-
tional value, as in the case of improved content of essen-
tial aminoacids. Lysine, for instance, is an essential amino
acid necessary for human health, which has to be intro-
duced through the diet since humans are not able to syn-
thesize it. In the selected maize lines, Illinois High Pro-
tein (IHP), whose extremely high protein value is however
affected by no lysine content against a too high level of
zein, RNAi anti a-zeins have been obtained by Agrobac-
terium-mediated transfer of a construct carrying inverted
repeated gene sequences encoding RNAs for silencing the
22- and 19-kDa a-zeins (153). Analysis of protein content
showed a change in protein composition, in particular
concerning the ratios of zein and non-zein fractions of
total proteins. Moreover, whilst an increase of lysine re-
sulted in seeds with enhanced nutritional value, an incom-
plete a-zein reduction maintained a desired property of
the kernel, i.e. a vitreous, hard endosperm. This result
proved that RNAi strategy is effective for obtaining ker-
nels where three relevant traits (high-protein and high-
-lysine contents and vitreous, hard endosperm) are com-
bined, i.e. a result that has never been achieved by con-
ventional breeding.
In food improvement, RNAi can also be applied to
silence the genes coding for antinutritional or harmful
components. In plants, a very attractive application of
gene silencing is the reduction of the allergenic proper-
ties of plant-derived food, and some interesting research
has already been developed in this framework. In peanut,
RNAi technology was used to eliminate the immunodo-
minant Ara h 2 protein, the major allergen in peanut by
transferring into peanut hypocotyls, via Agrobacterium, the
inverted repeats of the coding region of Ara h 2 genomic
DNA cloned in the a RNAi-inducing plant transforma-
tion vector pHANNIBAL. Crude extracts of several trans-
genic seeds of the T0 plants showed the absence of this
protein and their allergenicity was checked as IgE-bind-
ing capacity in the sera of patients allergic to peanuts.
Showing, by ELISA test, a significant decrease in the IgE-
-binding capacity of transgenic seeds compared to the wild-
-type, the feasibility of alleviating peanut allergy by RNAi
technology was proved (154).
Allergenicity cross-reaction between pollen and ed-
ible crops is known to afflict the population who suffer
from allergies. This is the case of people who are allergic
to birch pollen and also become allergic to apple fruit
because of the immunological similarities between the
major allergen in birch, Bet v 1, and the major allergen
in apple, Mal d 1. To overcome this suffering, inhibition
of Mal d 1 expression in apple plants by RNA interfer-
ence has been successfully attempted (155). A T-DNA con-
struct coding for an intron-spliced hairpin RNA carrying
a Mal d 1-specific inverted repeat sequence, separated by
a Mal d 1-specific intron sequence, was introduced into
apple leaf explants via Agrobacterium. This construct effi-
ciently silenced the target gene, as confirmed by quanti-
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tative real-time PCR. Moreover, silencing was unaffected
by grafting and remained stable for more than 3 years,
throughout all the developmental stages (156). Among
other interesting examples of successful application of
RNAi for producing crops with reduced/absent allergen-
ic properties, it is worth mentioning soya bean, where
transgenic suppression was successful in down-regula-
tion of the major allergene P34 accumulation in seeds,
with no apparent negative consequences on the normal
seed development (157), and tomato, where the genes
for allergens Lyc e 1.01 and Lyc e 1.02 were successfully
silenced (158).
It has been observed that some substances that are
toxic for humans, are, however, very important for plants.
This is the case of gossypol, a natural phenol derived
from the cotton plant (genus Gossypium) with known
anti-insect properties. Whilst it has been estimated that
global cottonseed production would potentially provide
the protein requirement for half a billion people per year,
this plant is under-utilized as a food crop because of the
presence of toxic gossypol in the whole cotton plant, in-
cluding seeds. Accordingly, the elimination of gossypol
from cottonseed has been a long-standing goal of breed-
ers.
RNAi was successfully used to break down gossypol
biosynthesis in cottonseed by targeting a gene coding for
the key enzyme d-cadinene synthase (159). Transgenic
cotton was generated by transferring via Agrobacterium a
hairpin RNA construct carrying a trigger sequence of the
Gossypium hirsutum d-cadinene synthase gene, under the
control of a highly seed-specific cotton a-globulin B gene
promoter. The level and stability of gossypol in cotton-
seed and other tissues were determined in T1 and T2
plants and seeds. In seeds, gossypol quantity was signi-
ficantly reduced in a stable and heritable manner. More-
over, since the levels of gossypol and related terpenoids
in the foliage and floral parts were not decreased, and
thus their function in plant defense against insects and
diseases remained unaffected, this strategy proved to be
interesting for producing plants with both good agro-
nomical characteristics and enhanced food properties.
RNAi in animal-derived food
Applications of gene down-regulation or silencing may
also open up interesting perspectives in animal-derived
food. Myostatin null mice, for instance, generated by gene
targeting, showed a dramatic and widespread increase
in skeletal muscle mass compared to wild-type count-
erparts, due to an increased number of muscle fibres
without a corresponding increase in the amount of fat
(160). Accordingly, reduction of myostatin expression
could be an attractive application of gene silencing for
enhancing muscle development in the livestock industry,
in particular for beef animals, and would be a promising
alternative to the use of GH genes which, as pointed out
above, gave disappointing results in mammals.
Myostatin, in fact, also known as growth differentia-
tion factor 8 (GDF8), proved to have an inhibitory effect
on muscle differentiation and growth, as animals lacking
myostatin or treated with substances that block the bind-
ing of myostatin to its receptor showed significant muscle
hypertrophy (161). This protein has been the object of
various studies and myostatin genes have been charac-
terized and found to be highly conserved among ver-
tebrate species. Two breeds of cattle, Belgian Blue and
Piedmontese, which were characterized by increased
muscle mass because of their increased ability to convert
feed into lean muscle (double-muscling trait) proved to
carry mutations (nonsense and frame shift mutations) in
the myostatin coding sequence.
It should be pointed out, however, that the selection
of double-muscled animals has resulted in a huge increase
in the incidence of dystocia, i.e. difficult calf delivery, as
in double-muscled Belgian Blue cows, Caesarean section
is routinely required (over 90 %) for reducing calf losses
(162). The increased muscle mass and feed efficiency,
however, have been evoked as appealing features, balanc-
ing such a drawback (160).
Nonetheless, in mouse, another interesting selective
gene targeting strategy to interfere with the myostatin
pathway has been achieved, and it could open the door
to further application in cattle production where different
expression of traits between the sexes would be desirable.
This strategy is based on the generation of transgenic ani-
mals for the Y-chromosome-linked muscle-specific expres-
sion of a dominant negative myostatin pro-domain, which
resulted in the production of males showing a 5–20 %
increase in skeletal muscle mass, whilst females were non-
-transgenic and thus not affected in their growth pheno-
type (135).
Molecular strategies would also be promising tools
for preventing some fatal diseases, which also have del-
eterious effects in humans through ill animal consump-
tion, like the neurodegenerative prion diseases or trans-
missible spongiform encephalopathies, including scrapie
and the mad cow disease (BSE). In these syndromes,
a misfolded isoform of the cellular prion protein (PrP)
proved to accumulate and act as a novel infectious agent;
thus, the introduction of mutated prion protein genes,
gene knockout or RNAi-mediated knockdown of PrP ex-
pression would be expected to produce livestock ani-
mals resistant to prion diseases. Some research has been
done in mouse, and initial studies in sheep, goats and
cattle seem promising; in vitro assays with brain tissue
homogenates derived from PrP-deficient cattle produced
via PrP knockout demonstrated resistance to prion pro-
pagation and the cattle were apparently normal in all ana-
lysed aspects (135).
As for the improved nutritional value of milk, with
its relevant implications for health of the many human
adults who lack intestinal lactose-hydrolyzing enzyme
activity, an interesting application of RNAi would be the
reduced presence of lactose based on a-lactalbumin ex-
pression knock-down. Compared to transgenic knock-out,
which has already been obtained in experimental mouse
and resulted in the production of lactose-free milk, down-
-regulation would produce milk with the adequate lac-
tose content to allow osmotic regulation and concentra-
tion of milk (163). Similarly, RNAi knock-down expression
of the b-lactoglobulin gene would reduce the allergeni-
city of cow's milk (135).
Concluding Remarks
As described in this review, the opportunities offered
by molecular tools both in plants and animals for pro-
duction of food with enhanced quali-quantitative values
218 L. MARTINELLI et al.: Gene Transfer for Food Enhancement, Food Technol. Biotechnol. 51 (2) 208–223 (2013)
are quite numerous, and notable. Moreover, the amount
of new information, in particular the data continually ac-
cumulated with the genome projects, predicts even greater
potential. However, according to the state of the art, the
significant amount of research efforts fulfilled in the last
decades seems to have produced more promises than
concrete achievements to offer to the market.
A series of issues can be mentioned as explanations
for this drawback: first of all, the considerable amount
of resources and time required in order to acquire reli-
able knowledge on gene involvement in biological path-
ways related to food properties and to develop sound
techniques for applying the knowledge in the produc-
tion of goods for human nutrition. Besides, there is a se-
ries of central issues, including risk evaluation process,
bureaucratic approval, regulatory procedures and public
acceptability, which complement, whilst often delaying,
scientific achievements, as exemplified by the above-de-
scribed cases of Golden Rice, AquAdvantage® Salmon and
the surrogates for human breast milk for the newborn.
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